Abbott Laboratories (NYSE: ABT) has a price-to-earnings ratio that is above its average at 34.51x. The stock has a 36-month beta value of 0.73. Opinions on the stock are mixed, with 13 analysts rating it as a “buy,” 8 as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for ABT is 1.72B, and at present, short sellers hold a 0.83% of that float. On January 20, 2025, the average trading volume of ABT was 5.05M shares.
ABT) stock’s latest price update
Abbott Laboratories (NYSE: ABT)’s stock price has gone decline by -0.38 in comparison to its previous close of 113.91, however, the company has experienced a 1.04% increase in its stock price over the last five trading days. zacks.com reported 2025-01-16 that Evaluate the expected performance of Abbott (ABT) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
ABT’s Market Performance
ABT’s stock has risen by 1.04% in the past week, with a monthly rise of 0.76% and a quarterly drop of -3.68%. The volatility ratio for the week is 1.64% while the volatility levels for the last 30 days are 1.55% for Abbott Laboratories. The simple moving average for the past 20 days is 0.04% for ABT’s stock, with a 2.62% simple moving average for the past 200 days.
Analysts’ Opinion of ABT
Many brokerage firms have already submitted their reports for ABT stocks, with Oppenheimer repeating the rating for ABT by listing it as a “Outperform.” The predicted price for ABT in the upcoming period, according to Oppenheimer is $130 based on the research report published on October 08, 2024 of the previous year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see ABT reach a price target of $131. The rating they have provided for ABT stocks is “Overweight” according to the report published on September 19th, 2024.
ABT Trading at -1.36% from the 50-Day Moving Average
After a stumble in the market that brought ABT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.71% of loss for the given period.
Volatility was left at 1.55%, however, over the last 30 days, the volatility rate increased by 1.64%, as shares surge +0.17% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.54% lower at present.
During the last 5 trading sessions, ABT rose by +1.04%, which changed the moving average for the period of 200-days by +1.30% in comparison to the 20-day moving average, which settled at $113.44. In addition, Abbott Laboratories saw 0.33% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABT starting from Funck, Jr. Robert E., who proposed sale 15,000 shares at the price of $120.00 back on Nov 04 ’24. After this action, Funck, Jr. Robert E. now owns shares of Abbott Laboratories, valued at $1,800,000 using the latest closing price.
ALLEN HUBERT L, the EXECUTIVE VICE PRESIDENT of Abbott Laboratories, sale 157,421 shares at $117.04 during a trade that took place back on Oct 21 ’24, which means that ALLEN HUBERT L is holding 184,806 shares at $18,424,298 based on the most recent closing price.
Stock Fundamentals for ABT
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.55 for the gross margin
The net margin for Abbott Laboratories stands at 0.14. The total capital return value is set at 0.12. Equity return is now at value 14.87, with 7.85 for asset returns.
Based on Abbott Laboratories (ABT), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at 0.58. The debt to equity ratio resting at 0.38. The interest coverage ratio of the stock is 13.9.
Currently, EBITDA for the company is 10.61 billion with net debt to EBITDA at 0.69. When we switch over and look at the enterprise to sales, we see a ratio of 4.96. The receivables turnover for the company is 4.48for trailing twelve months and the total asset turnover is 0.55. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.60.
Conclusion
To sum up, Abbott Laboratories (ABT) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
